Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucose-6-phosphatase catalytic subunit 3 (G6PC3) is an integral membrane enzyme localized in the endoplasmic reticulum, where it catalyzes the hydrolysis of glucose-6-phosphate to glucose and phosphate—the final reaction in gluconeogenesis and glycogenolysis. Unlike the liver-predominant G6PC isoforms, G6PC3 is expressed ubiquitously and is essential for normal glucose metabolism and neutrophil function. Mutations in the G6PC3 gene cause autosomal recessive severe congenital neutropenia, sometimes with syndromic features including cardiovascular and urogenital anomalies. There are no approved drugs that directly target G6PC3, but its mutation is diagnostic for specific congenital disorders. Loss of function can cause life-threatening metabolic and immune consequences through disruption of cellular glucose production and neutrophil viability.
N/A (no specific targeted therapies at present)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glucose-6-phosphatase catalytic subunit 3 (G6PC3).